Summary

Other Scenarios:

Buyer: Protherics PLC (ADR) (PTIL) Last Price: 15.98 Market Cap.: 3.87B
Target: King Pharmaceuticals (KG) Last Price: 15.83 Market Cap.: 3.83B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 865
Biopharmaceuticals 319
Medical Devices   247
Outsourced Services   68
Veterinary Products and Services   7

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business

Buyer (Total: 9)
  • Angiotensin Vaccine
  • CytoFab
  • Prolarix
  • VEGF Vaccine
Target (Total: 78)
  • Adrenalin Chloride Solution (Epinephrine)
  • Corgard (Nadolol)
  • Adenocard (Adenosine)
  • Procanbid (Procainamide Hydrochloride)
Buyer
  • Protherics Enfer TSE Diagnostic Kit
Target
  • Meridian Medical Technologies Prime ECG Electrocardiac Mapping System
  • Binodenoson
  • Meridian Medical Technologies Teleweight Monitoring System
  • Meridian Medical Technologies CardioBeepers

Business Relationship Summary:

Top Key Suppliers

Top Key Customers

Buyer (Total: 2)
  • Symbion Health Limited (SYHTY)
  • Chesapeake Biological Laboratories
Target (Total: 2)
  • sanofi-aventis (ADR) (SNY)
  • Inyx, Inc. (IYXI)
Buyer (Total: 1)
  • U.S. Department of Defense
Target (Total: 8)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Cardinal Health, Inc. (CAH)
  • QLT Inc. (USA) (QLTI)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 211 2,795
Revenue Per Employee n/a 693,664.8
Total Revenue 19.4 484.2
Total Expenses 26.0 411.0
Other Revenue 0.0 0.0
Cost of Revenue 13.9 92.4
SG&A Expense 7.7 167.4
Research & Development 4.3 29.9
Other Operating Expense 0.0 0.0
Operating Income -6.5 73.3
Unusual Income 0.0 87.0
LT Debt to Capital 17.54 16.44
Fwd P/E n/a 10.29
Fwd P/Rev n/a 2.08
Book Value 43.2 2,032.4
Curr Portion of LTD/Cap Lease 1.1 180.0

Key Ratios

  Buyer Target
Gross Margin % 36.18 81.83
Operating Margin % -32.51 7.49
Quick Ratio 1.16 1.42
Current Ratio 2.22 1.91
Coverage Ratio 0.05 0.08
Total Assets 68.9 3,217.1
Return on Equity % -25.47 4.94
Return on Assets % -15.96 3.12
Cash+ ST Inv. Per Share 0.05 3.36
Total Debt 10.3 580.0
Total Debt to Equity % 23.87 28.54
Total Debt to Tangible Equity % 42.18 61.77
Debt to Asset % 14.96 18.03

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Protherics PLC (Protherics) is a biopharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products largely for the treatment of human diseases. It is focused on the development, manufacture and marketing of products for critical care and cancer. The Company's products under development include CroFab, DigiFab, TSE Testing, ViperaTAb, Voraxaze, CytoFab, Prolarix and Angiotensin Vaccine. The Company's operations are located in the United Kingdom, North America and Australia. Within the Company's primary business segment of the sale, manufacture and development of pharmaceutical products, there are two areas, which it develops over the long term: a critical care business based on its ovine polyclonal antibody technology platform, and a cancer business.

Target

King Pharmaceuticals, Inc. (King) is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products. The Company operates through five segments: Branded pharmaceuticals, Meridian Medical Technologies, Royalties, Contract manufacturing and other. King's branded pharmaceutical products can be divided primarily into six therapeutic areas: cardiovascular/ metabolic (including Altace, Corgard, Levoxyl and Cytomel); neuroscience (including Sonata and Skelaxin), hospital/ acute care (including Thrombin-JMI, Bicillin, Synercid and Intal), and other. Meridian Medical Technologies segment consists of its auto-injector business, which includes EpiPen. In March 2006, the Company acquired the rights to market and sell EpiPen throughout Canada until 2015. In addition, the Company manufactures pharmaceutical products under contracts with a variety of pharmaceutical and biotechnology companies.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
 
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
 
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
 
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
 
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
 
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
 
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
 
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
 
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
 
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
 
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
 
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
 
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
 
Medical Devices  
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
 
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
 
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
 
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
 
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
 
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Buyer Products:

  • Protherics Enfer TSE Diagnostic Kit
 

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Systemic  
Anaphylactic Shock  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that treat allergic shock by stimulating alpha and beta adrenergic receptors.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
 
Cardiovascular System
Heart Disorders  
Angina  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.

Target Products:

  • Corgard (Nadolol)
 
Arrhythmia  
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction

Target Products:

  • Adenocard (Adenosine)
 
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Target Products:

  • Procanbid (Procainamide Hydrochloride)
 
Heart Failure (HF)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
 
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
 
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Angiotensin Vaccine
 
Vascular Disorders  
Hypertension  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
 
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Target Products:

  • Corgard (Nadolol)
 
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Corzide (Nadolol/Bendroflumethiazide)
 
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
 
Dermatology  
Lesion/Scaling Disorders  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site, as well as prevent the growth of bacteria.

Target Products:

  • Cortisporin (Neomycin/Polymyxin B Sulfates/Hydrocortisone Acetate) Cream/Ointment
 
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.

Target Products:

  • Tigan (Trimethobenzamide Hydrochloride)
 
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
 
Endocrinology/Metabolism  
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Target Products:

  • Florinef (Fludrocortisone Acetate)
 
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Target Products:

  • Pitressin (Vasopressin)
 
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
  • Menest (Esterified Estrogens Tablets)
 
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MRE0094 (Adenosine A2a Receptor Agonist)
  • ANDROSORB (Testosterone)
 
Pituitary Gland Disorders  
Hypopituitarism  
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
 
Pituitary Hyperthyroidism (TSH-Induced)  
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
 
Severe Short Stature  
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
 
Reproductive Disorders  
Hypogonadism  
Female  
Hormonal Treatments  
Estrogens
Therapeutics that are female sex hormones.

Target Products:

  • Menest (Esterified Estrogens Tablets)
 
Menopause  
Estrogens
Therapeutics that are female sex hormones.

Target Products:

  • Menest (Esterified Estrogens Tablets)
 
Thyroid Gland Disorders  
Hyperthyroidism  
Thyroid Hormone Synthesis Inhibitors
Therapeutics that stop the production of thyroid hormones.

Target Products:

  • Tapazole (Methimazole)
 
Hypothyroidism  
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
  • Triostat (Liothyronine Sodium)
  • Cytomel (Liothyronine Sodium)
 
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.

Target Products:

  • Coly-Mycin M Parenteral (Colistimethate Sodium)
 
Carbacephems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Target Products:

  • Lorabid (Loracarbef)
 
Monobactams
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.

Target Products:

  • Chloromycetin Sodium Succinate
 
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.

Target Products:

  • Bicillin C-R/C-R 900/300/C-R Pediatric (Penicillin G Benzathine/Penicillin G Procaine Injectable Suspension)
  • Bicillin L-A/L-A Pediatric (Penicillin G Benzathine Injectable Suspension)
  • Penicillin G Procaine Injectable Suspension
 
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Synercid (Quinupristin/Dalfopristin)
 
Narrow Spectrum  
Dermatology  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotics)
Therapeutics that treat bacterial infections of the skin with a steroidal compound and a compound that kills or inhibits the growth of bacteria.

Target Products:

  • Cortisporin (Neomycin/Polymyxin B Sulfates/Hydrocortisone Acetate) Cream/Ointment
 
Skin/Soft Tissue Infections  
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
 
Musculoskeletal System  
Skin/Soft Tissue Infections  
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
 
Ophthalmology  
Conjunctivitis  
Chloramphenicols
Therapeutics that treat inflammation of the clear membrane outside the eye by preventing amino acids from binding together to form proteins.

Target Products:

  • Chloromycetin Ophthalmic (Chloramphenicol)
 
Ocular Infections  
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.

Target Products:

  • Neosporin Ophthalmic (Neomycin Sulfate B/Polymyxin Sulfate B/Gramicidin) Ointment/Solution Sterile
 
Aminoglycosides/Polypeptides/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis, damaging the cell membrane, and suppressing the full immune response.

Target Products:

  • Cortisporin Opthalmic (Neomycin/Polymyxin B Sulfates/Bacitracin Zinc/Hydrocortisone) Ointment/Suspension Sterile
 
Polypeptides
Therapeutics that treat bacterial infections of the eye by damaging the cell membrane.

Target Products:

  • Polysporin (Bacitracin Zinc/Polymyxin B Sulfate)
 
Otolaryngology (Ear/Nose/Throat)  
External Ear Canal Infections  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that treat bacterial infections of the external auditory canal with a steroidal compound and by killing or inhibiting the growth of microorganisms.

Target Products:

  • Cortisporin-TC Otic (Colistin Sulfate/Neomycin Sulfate/Thonzonium Bromide/Hydrocortisone Acetate)
  • Cortisporin Otic (Neomycin/Polymyxin B Sulfate/Hydrocortisone) Solution/Suspension Sterile
  • Coly-Mycin S Otic (Colistin Sulfate/Neomycin Sulfate/Thonzonium Bromide/Hydrocortisone Acetate)
  • Pediotic Suspension Sterile (Neomycin/Polymyxin B Sulfates/Hydrocortisone)
 
Otitis Media  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
 
Respiratory System  
Bronchitis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
 
Pneumonia  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
 
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Aminoglycosides
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial protein synthesis.

Target Products:

  • Neosporin G.U. Irrigant (Neomycin Sulfate/Polymyxin B Sulfate)
 
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
 
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.

Target Products:

  • Proloprim (Trimethoprim) Tablets
 
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • CytoFab

Target Products:

  • HPV-16 Virus-Like Particle (VLP) Vaccine
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Amebiasis  
Aminoglycosides
Therapeutics that treat infections by an amoeba by inhibiting protozoal protein synthesis.

Target Products:

  • Humatin (Paramomycin Sulfate)
 
Viral  
DNA Viruses  
Herpesvirus  
Herpes Simplex Type 1  
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA blocking the action of an essential enzyme.

Target Products:

  • Viroptic Ophthalmic Solution (Trifluridine)
 
Herpes Simplex Type 2  
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by blocking the action of an essential enzyme.

Target Products:

  • Viroptic Ophthalmic Solution (Trifluridine)
 
Musculoskeletal System  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Hormonal Treatments  
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
 
Neurology  
Neurological Disorders  
Epilepsy  
Status Epilepticus  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat status epilepticus by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Vanquix (Diazepam Auto-Injection)
 
Neuromuscular Disorders  
Parkinson`s Disease (PD)  
Adjunctive Treatments  
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.

Target Products:

  • Kemadrin (Procyclidine Hydrochloride)
 
Psychiatric Disorders  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Target Products:

  • Sonata CIV (Zaleplon)
 
Obstetrics/Gynecology  
Child Birth/Pregnancy  
Induction/Cervical Ripening  
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.

Target Products:

  • Pitocin (Oxytocin)
 
Female Genital Disorders  
Ovarian  
Hypogonadism  
Hormonal Treatments  
Estrogens
These are female sex hormones.

Target Products:

  • Menest (Esterified Estrogens Tablets)
  • Delestrogen (Estradiol Valerate Injection, USP)
 
Vulvovaginal  
Atrophy  
Hormonal Treatments  
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
  • Menest (Esterified Estrogens Tablets)
 
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Bremelanotide/PT-141 (Alpha Melanocyte-Stimulating Hormone Analog)
 
Oncology
Breast Cancer  
Palliative Agents  
Hormonal Treatments  
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.

Target Products:

  • Menest (Esterified Estrogens Tablets)
 
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Prolarix
 
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • VEGF Vaccine
  • Metalloorganic
 
Urology  
Prostate Cancer  
Palliative Agents  
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.

Target Products:

  • Menest (Esterified Estrogens Tablets)
 
Ophthalmology  
Degenerative Disorders  
Irritation/Inflammation  
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.

Target Products:

  • Chloromycetin Ophthalmic (Chloramphenicol)
  • Polysporin (Bacitracin Zinc/Polymyxin B Sulfate)
  • Neosporin Ophthalmic (Neomycin Sulfate B/Polymyxin Sulfate B/Gramicidin) Ointment/Solution Sterile
 
Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat infections by inhibiting bacterial replication as well as prevent cells that cause inflammation from adhering to the inflammation site.

Target Products:

  • Cortisporin Opthalmic (Neomycin/Polymyxin B Sulfates/Bacitracin Zinc/Hydrocortisone) Ointment/Suspension Sterile
 
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.

Target Products:

  • Ketalar CIII (Ketamine Hydrochloride)
 
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.

Target Products:

  • Brevital Sodium C-IV (Methohexital Sodium)
 
Primary  
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.

Target Products:

  • Brevital Sodium C-IV (Methohexital Sodium)
 
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Remoxy (Time-Release Oxycodone)
 
Non-Narcotics  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Target Products:

  • Skelaxin (Metaxalone)
 
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • T-62
 
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
 
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
 
Prophylactic Treatments  
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.

Target Products:

  • Intal HFA (Cromolyn Sodium)
  • Tilade (Nedocromil Sodium)
 
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
 
Bronchitis  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
 
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
 
Bronchospasm  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
 
Emphysema  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
 
Upper Respiratory Tract Disorders  
Coughs/Colds  
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.

Target Products:

  • Tussigon Tablets CIII (Hydrocodone Bitartrate/Homatropine Methylbromide)
 
Antihistamines/Decongestants/Anticholinergics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and blocking acetylcholine receptors.

Target Products:

  • Drize-R (Chlorpheniramine Maleate/Phenylephrine Hydrochloride/Methscopolamine Nitrate)
 
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.

Target Products:

  • VANEX-HD CIII (Hydrocodone Bitartrate/Phenylephrine HCI/Chlorpheniramine)
  • Endagen HD CIII (Hydrocodone Bitartrate/Phenylephrine Hydrochloride/Chlorpheniramine Maleate)
 
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.

Target Products:

  • Nucofed Capsules/Syrub CIII (Codeine Phosphate/Pseudoephedrine Hydrochloride)
 
Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and relieving pain and fever.

Target Products:

  • Tussend CIII (Hydrocodone Bitartrate/Pseudoephedrine Hydrochloride/Chlorpheniramine)
 
Decongestants/Antitussives/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and helping in the ejection of the mucous.

Target Products:

  • Nucofed Expectorant/Pediatric Expectorant (Codeine Phosphate/Pseudoephedrine Hydrochloride/Guaifenesin)
  • Tussend Expectorant CIII (Hydrocodone Bitartrate/Pseudoephedrine Hydrochloride/Guaifenesin)
 
Surgery  
General  
Hemorrhage  
Coagulating Agents (Coagulants)
Therapeutics that treat bleeding during a surgical procedure by promoting blood clotting.

Target Products:

  • Thrombin JMI
 
Toxicology
Animal Poisoning  
Snakes  
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.

Buyer Products:

  • CroFab [(Crotalidae Polyvalent Immune Fab (Ovine)]
 
Chemical Poisoning
Digoxin  
Digoxin Binding Agents
Therapeutics that treat toxicity due to ingestion of excessive digoxin by competitively binding to digoxin, making them unavailable for binding at their site of action on cells in the body.

Buyer Products:

  • DigiFab [Digoxin Immune Fab (Ovine)]
 
Methotrexate  
Carboxypeptidase
Therapeutics that treat methotrexate toxicity by catalyzing its carboxyl groups.

Buyer Products:

  • Voraxaze
 
Nerve Gas  
Anticholinergic Agents
Therapeutics that treat toxicity due to nerve agent/gas by antagonizing the muscarine-like actions of acetylcholine and other choline esters.

Target Products:

  • AtroPen (Atropine)
 
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Bremelanotide/PT-141 (Alpha Melanocyte-Stimulating Hormone Analog)
 
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
 
Renal Insufficiency  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that delay or treat kidney disease by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
 
Wound Management  
Burns  
Complications  
Infections  
Antibacterial Agents (Antibiotics)  
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
 
Antifungal Agents  
Sulfonamides
Therapeutics that treat fungal infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
 
Medical Devices  
Cardiology  
Diagnostic  
Monitoring  
Monitors  
Electrocardiogram (ECG/EKG)  
Interpretive/Analysis
Specialized electrocardiogram devices that facilitate certain diagnostic functions and analysis.

Target Products:

  • Meridian Medical Technologies Prime ECG Electrocardiac Mapping System
 
Stress/Exercise Test
Instruments used to evaluate the cardiopulmonary system during exercise.

Target Products:

  • Binodenoson
 
Telemetry  
Telemetry Systems
Complete systems or devices used to facilitate transfer of vitals monitoring data from the patient's site to a central monitor.

Target Products:

  • Meridian Medical Technologies Teleweight Monitoring System
  • Meridian Medical Technologies CardioBeepers
  • Meridian Medical Technologies CardioPocket
  • Meridian Medical Technologies TelePulse Oximeter
  • Meridian Medical Technologies Transtelephonic Blood Pressure Monitors
 
Clinical Diagnostics  
Immunoassays  
Reagents  
Test Kits  
Bacterial  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Target Products:

  • Aplisol (Tuberculin Purified Protein Derivative)
 
Drug Delivery  
Percutaneous (Subcutaneous/Intramuscular/Intravenous)  
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.

Target Products:

  • Meridian Medical Technologies Auto-Injector Technology
  • Meridian Medical Technologies Wet/Dry Auto-Injector Technology
 
Radiology  
Nuclear  
Gamma Camera  
Contrast Agents  
Radionuclides  
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.

Target Products:

  • Adenoscan
 
Outsourced Services  
Development/Manufacturing Services  
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.

Target Products:

  • Meridian Medical Technologies Contract Development Services
 
Contract Manufacturing Organizations (CMO)  
Medical Devices
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.

Target Products:

  • Meridian Medical Technologies Contract Manufacturing Services
 
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Target Products:

  • King Pharmaceuticals Contract Manufacturing Services
  • Meridian Medical Technologies Contract Manufacturing Services
 
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.

Target Products:

  • King Pharmaceuticals Contract Manufacturing Services
 
Veterinary Products and Services  
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.

Buyer Products:

  • Protherics Enfer TSE Diagnostic Kit
 

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Target
  Pfizer Inc. n/a 165,892.112 14.04 11.21 3.26 3.24 9.32
GlaxoSmithKline plc (ADR) n/a 157,188.981 17.23 15.95 3.83 3.75 18.10
sanofi-aventis (ADR) n/a 131,722.813 46.37 13.90 3.66 3.65 n/a
Wyeth n/a 58,252.673 15.69 14.00 3.06 2.92 6.50
Bristol Myers Squibb Co. n/a 50,160.697 15.74 21.54 2.59 2.63 10.73
Forest Laboratories, Inc. n/a 12,075.387 17.71 15.72 4.08 3.75 4.89
Shire plc (ADR) n/a 7,022.113 n/a 24.97 4.19 3.90 8.83
Biovail Corporation (USA) n/a 3,598.723 12.44 9.72 3.66 3.48 12.73
Watson Pharmaceuticals, Inc. n/a 2,585.826 20.34 18.93 1.56 1.43 2.72
Medicis Pharmaceutical Corporation n/a 1,326.563 n/a 23.14 3.91 3.80 8.09
Cubist Pharmaceuticals n/a 1,263.558 n/a -203.27 9.22 5.90 -114.46
Sciele Pharma Inc. n/a 817.344 19.11 18.86 3.38 2.81 20.29
Impax Laboratories Inc. n/a 385.999 768.78 9.70 3.43 1.90 6.58
Neurocrine Biosciences, Inc. n/a 371.849 n/a -6.08 2.83 4.74 0.97
Somaxon Pharmaceuticals, Inc. n/a 270.681 n/a -5.31 n/a 2.49 3.35
Vanda Pharmaceuticals Inc. n/a 194.536 n/a -2.22 n/a 0.00 13.83
Omrix Biopharmaceuticals, Inc. n/a 164.539 92.23 22.58 5.00 2.90 -67.02
Avigen, Inc. n/a 144.512 n/a -5.42 11.92 1,447.62 2.49
Lannett Company, Inc. n/a 137.123 n/a 26.36 2.54 2.30 2.28
Medicure Inc. (USA) n/a 109.491 n/a n/a 618.79 n/a 10.99
Advancis Pharmaceutical Corporation n/a 90.911 n/a -2.72 6.95 5.23 5.15
BioDelivery Sciences International, Inc. n/a 24.613 n/a n/a 30.40 n/a -6.13

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Symbion Health Limited n/a 1,616.118 26.73 n/a 0.55 n/a 5.61
Chesapeake Biological Laboratories n/a n/a n/a n/a n/a n/a n/a
Target
  sanofi-aventis (ADR) n/a 131,722.813 46.37 13.90 3.66 3.65 n/a
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  U.S. Department of Defense n/a n/a n/a n/a n/a n/a n/a
Target
  McKesson Corporation 27.00% 13,901.343 18.32 17.27 0.16 0.15 3.54
AmerisourceBergen Corp. 14.00% 8,599.595 25.18 19.59 0.15 0.15 4.52
Cardinal Health, Inc. n/a 26,242.697 28.31 20.29 0.33 0.33 6.97
QLT Inc. (USA) n/a 612.516 n/a 12.54 2.68 3.06 1.45
Salix Pharmaceuticals Ltd n/a 547.089 n/a 17.91 3.26 2.65 3.54
Medicare/Medicaid/Other Government Programs n/a n/a n/a n/a n/a n/a n/a
Federal Government Agencies (United States) n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  AstraZeneca PLC (ADR) n/a 89,835.545 17.89 15.55 3.68 3.54 8.51
Altana AG (ADR) n/a 7,352.795 12.65 12.51 1.64 n/a 3.96
Symbion Health Limited n/a 1,616.118 26.73 n/a 0.55 n/a 5.61
Chesapeake Biological Laboratories n/a n/a n/a n/a n/a n/a n/a
Promega Corporation n/a n/a n/a n/a n/a n/a n/a
Enfer Scientific Ltd. n/a n/a n/a n/a n/a n/a n/a
Swedish Orphan AB n/a n/a n/a n/a n/a n/a n/a
Target
  sanofi-aventis (ADR) n/a 131,722.813 46.37 13.90 3.66 3.65 n/a
Eli Lilly & Co. n/a 61,366.108 29.64 17.44 4.13 4.00 5.25
Wyeth n/a 58,252.673 15.69 14.00 3.06 2.92 6.50
Barr Pharmaceuticals, Inc. n/a 5,069.560 16.90 15.55 4.08 3.99 4.51
Arrow International, Inc. n/a 1,501.443 33.09 26.77 3.25 3.17 3.66
QLT Inc. (USA) n/a 612.516 n/a 12.54 2.68 3.06 1.45
Salix Pharmaceuticals Ltd n/a 547.089 n/a 17.91 3.26 2.65 3.54
Pain Therapeutics, Inc. n/a 369.619 n/a 76.00 18.11 5.98 5.58
Palatin Technologies, Inc. n/a 160.185 n/a n/a 7.77 n/a 157.66
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a
Suntory Group n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
United Research Laboratories and Mutual Pharmaceutical Company n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 34.0 1,888.5 1,922.5
Other Revenue 0.0 0.0 0.0
Total Revenue 34.0 1,888.5 1,922.5
Cost of Revenue 21.7 343.2 364.9
SG&A Expense 14.3 656.8 671.1
Depreciation & Amortization 0.0 140.0 140.0
Research & Development 9.1 92.4 101.5
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 -0.8 -0.8
Unusual Expense (Income) 0.0 515.5 515.5
Total Expenses 45.1 1,747.1 1,792.2
Operating Income -11.1 141.4 130.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -0.5 10.7 10.2
Other, Net 0.0 -2.3 -2.3
Income Before Taxes -11.6 149.8 138.2
Income Taxes -0.6 49.5 48.9
Income After Taxes -11.0 100.4 89.4
Net Income - Excl. Xord. Items -11.0 100.4 89.4
Discontinued Operations 0.0 -1.9 -1.9
Net Income - Incl. Xord. Items -11.0 98.5 87.5
Income Avail. to Common -11.0 98.5 87.5
Share Items
Basic Avg. Shares Outstanding 243.0 242.0 485.0
Basic EPS - Excl. Xord. Items -0.05 0.41 0.18
Basic EPS - Incl. Xord. Items -0.05 0.41 0.18
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 243.0 242.6 485.5
F.D. EPS - Excl. Xord. Items -0.05 0.41 0.18
F.D. EPS - Incl. Xord. Items -0.05 0.40 0.18
Balance Sheet
Assets
Cash and Equivalents 11.4 328.3 339.7
ST Investments 0.0 486.2 486.2
Accounts Receivable 7.8 268.3 276.1
Inventory 17.5 217.3 234.8
Prepayments and Advances 0.0 82.0 82.0
Other Current Assets 0.0 75.6 75.6
Current Assets 36.7 1,457.7 1,494.4
Accum D&A 0.0 0.0 0.0
PPE, Net 12.6 302.2 314.8
Goodwill & Intangibles 18.7 1,093.5 1,112.3
Long Term Investments 0.0 15.5 15.5
Other Assets 0.0 0.0 0.0
Other LT Assets 0.8 348.3 349.1
Total Assets 68.9 3,217.1 3,286.1
Liabilities
Accounts Payable 14.4 69.4 83.7
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 440.5 440.5
ST Debt 0.1 0.0 0.1
Curr Port of LTD & Cap Lease Oblg 1.1 180.0 181.1
Other (Current) Liabilities 1.1 75.0 76.0
Current Liab. 16.5 764.8 781.4
LT Debt 6.9 400.0 406.9
Capitalized Lease Obligations 2.3 0.0 2.3
Total LT Debt 9.2 400.0 409.2
Other LT Liab. 0.0 19.9 19.9
Total Liabilities 25.7 1,184.7 1,210.4
Shareholders Equity
Common Stock 8.9 1,224.1 1,233.0
Additional Paid in Capital 142.9 0.0 142.9
Retained Earnings -109.2 805.6 696.4
Other Equity 0.6 2.7 3.3
Total Equity 43.2 2,032.4 2,075.6
Total Liab. & Equity 68.9 3,217.1 3,286.1
Shares Outstanding 243.0 242.2 485.2
Cash Flow
Operating Cash Flow
CF Net Income -11.1 0.0 -11.1
CF Depreciation 2.5 0.0 2.5
CF Amortization 0.2 0.0 0.2
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 1.8 -1.2 0.6
Change in Working Capital 1.6 491.6 493.2
Total Cash From Operating Activities -5.0 490.4 485.4
Investing Cash Flow (not calculated)
Capital Expenditures -1.6 -95.5 -97.1
Other Investing Cash Flows 0.6 -348.8 -348.2
Total Cash From Investing Activities -1.0 -444.3 -445.3
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -0.2 7.3 7.1
Purchase and Retirement of Debt -0.7 236.6 235.9
Other Financing Cash Flow -0.9 -10.3 -11.3
Total Cash From Financing Activities -2.7 233.6 230.9
Exchange Rate Effects -0.0 0.0 -0.0
Net Change in Cash -8.7 279.7 271.0
Cash Taxes Paid 0.0 107.2 107.2
Cash Interest Paid 0.9 10.6 11.5